1. Home
  2. CRNX vs MHO Comparison

CRNX vs MHO Comparison

Compare CRNX & MHO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$33.65

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

MHO

M/I Homes Inc.

HOLD

Current Price

$118.66

Market Cap

3.3B

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRNX
MHO
Founded
2008
1976
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Homebuilding
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
3.3B
IPO Year
2018
1995

Fundamental Metrics

Financial Performance
Metric
CRNX
MHO
Price
$33.65
$118.66
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
2
Target Price
$74.78
$160.00
AVG Volume (30 Days)
1.0M
188.2K
Earning Date
05-07-2026
04-22-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
14.74
Revenue
$1,039,000.00
$4,417,781,000.00
Revenue This Year
$722.66
$0.66
Revenue Next Year
$183.79
$6.97
P/E Ratio
N/A
$8.26
Revenue Growth
N/A
N/A
52 Week Low
$24.10
$100.22
52 Week High
$57.99
$158.92

Technical Indicators

Market Signals
Indicator
CRNX
MHO
Relative Strength Index (RSI) 29.20 27.65
Support Level $33.23 $118.03
Resistance Level $37.23 $121.55
Average True Range (ATR) 1.62 3.38
MACD 0.13 -0.82
Stochastic Oscillator 8.33 6.85

Price Performance

Historical Comparison
CRNX
MHO

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

About MHO M/I Homes Inc.

M/I Homes Inc is an American construction company that focuses on residential construction. It consists of two distinct operations: homebuilding and financial services. The homebuilding operations are spread into the Midwest, Mid-Atlantic, and Southern regions, and the financial services operations support homebuilding operations by providing mortgage loans and title services to the customers of homebuilding operations. Homebuilding operations comprises a predominant portion of the revenue. The company builds homes and communities that target entry-level, move-up, and luxury homebuyers.

Share on Social Networks: